Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Centre Henri Becquerel, Amiens, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Post-menopausal woman without superior age limit
No metastatic breast cancer, stade I-II, estrogen receptor positive or progesterone receptor positive, treated by conservative surgery or total mastectomy and requiring additive treatment by radiotherapy and hormonotherapy
The patients including in another clinical trial can be include in this observatory

Treatment and study plan

Primary outcomes

radiation side effects

Time frame: 5 years after the end of radiotherapy

Describe, in real situation, the ionisant radiation effects on the healthy tissues in patients receiving anastrazole in association or sequential with radiotherapy

Sponsors and collaborators

Lead sponsor

Centre Oscar Lambret

Other

Registry information

Acronym: ORACLES

Important dates

Study start: 2005
Primary completion: 2015
Study completion: 2016
First posted: Aug 18, 2010
Registry last updated: May 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed